Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1096

Sort by

Sort Order Select

Journal Articles

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Waleed Ghanima, Terry Gernsheimer, David J. Kuter

Blood (2021) 137 (20): 2736–2744.

https://doi.org/10.1182/blood.2021010968

Published: 2021

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Management of pyruvate kinase deficiency in children and adults

Rachael F. Grace, Wilma Barcellini

Blood (2020) 136 (11): 1241–1249.

https://doi.org/10.1182/blood.2019000945

Published: 2020

Journal Articles

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

Alessandro Malara, PhD, Cristian Gruppi, PhD, Margherita Massa, Vittorio Rosti, MD, Giovanni Barosi, Alessandra Balduini, MD

Blood (2019) 134 (Supplement_1): 1688.

https://doi.org/10.1182/blood-2019-130735

Published: 2019

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Second-Line Therapy for Immune Thrombocytopenia: Real-World Experience

Hasmik Nazaryan, Yang Liu, MS, Emily Sirotich, BS, Joanne M Duncan, MSc, Donald M. Arnold, MD

Blood (2019) 134 (Supplement_1): 2120.

https://doi.org/10.1182/blood-2019-128336

Published: 2019

Journal Articles

Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)

Omar Niss, MD, Robert B. Lorsbach, MD PhD, David K. Buchbinder, MD MSHS, Satheesh Chonat, MD, Morgan L. McLemore, MD, Timothy McCavit, MD, Jeffrey H Schwartz, MD, Jessica Meznarich, MD, Katie Seu, Wenying Zhang, MD PhD, Theodosia A. Kalfa, MD PhD

Blood (2019) 134 (Supplement_1): 3521.

https://doi.org/10.1182/blood-2019-128975

Published: 2019

Journal Articles

Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency

Blood (2019) 134 (Supplement_1): 2175.

https://doi.org/10.1182/blood-2019-123069

Published: 2019

Journal Articles

Erythropoietin Downregulates Red Blood Cell Clearance in Mice

Martin Colard, MD, Michaël Dussiot, PhD, Anaïs Martinez, Carole Peyssonnaux, PhD, Patrick Mayeux, PhD, Fleur Samantha Benghiat, MD PhD, Pierre Buffet, MD PhD, Olivier Hermine, MD PhD, Pascal Amireault, PhD

Blood (2019) 134 (Supplement_1): 3524.

https://doi.org/10.1182/blood-2019-126768

Published: 2019

Journal Articles

Development of Patient-Reported Outcome Measures (Symptoms and Impacts) in Adults with Pyruvate Kinase Deficiency

Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Audra N. Boscoe, PhD, Chris Evans, PhD, Shayna Egan, MPH, Ted Wells, Sarah Piantedosi, Jennifer Cohen, Robert J Klaassen, MD FRCPC, Rachael F. Grace, MD, Mike Storm, MSc

Blood (2019) 134 (Supplement_1): 3447.

https://doi.org/10.1182/blood-2019-128524

Published: 2019

Journal Articles

Oryzocytosis: A Novel Morphological Variant of Hereditary Elliptocytosis Associated with a Novel Mutation in β-Spectrin ( SPTB c154 C>T p.Arg52Trp)

Alexander Glaros, MD, Manisha Gadgeel, MBBS, MS, Shruti Bagla, PhD, Steven Buck, MS, Roland Chu, MD, Yaddanapudi Ravindranath, MBBS, Brian Edwards, PhD, Asmita Vaishnav

Blood (2019) 134 (Supplement_1): 3509.

https://doi.org/10.1182/blood-2019-131219

Published: 2019

Journal Articles

Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency

Kathryn Addonizio, BA, Hanny Al-Samkari, MD, Bertil Glader, MD PhD, D Holmes Morton, MD, Satheesh Chonat, MD, Alexis A. Thompson, MD MPH, Kevin H. M. Kuo, MDMSc,FRCPC, Yaddanapudi Ravindranath, MBBS, Heng Wang, MD PhD, Jennifer A. Rothman, MD, Janet L. Kwiatkowski, MD MSCE, Charles Kung, PhD, Penelope A. Kosinski, MS, Hasan Al-Sayegh, MS, Wendy B. London, PhD, Rachael F. Grace, MD

Blood (2019) 134 (Supplement_1): 3515.

https://doi.org/10.1182/blood-2019-125248

Published: 2019

Journal Articles

Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study

Rachael F. Grace, MD, D. Mark Layton, MB BS, FRCP, FRCPCH, Frédéric Galactéros, MD PhD, Wilma Barcellini, MD, Eduard J. van Beers, MD PhD, Hassan M. Yaish, MD, Yaddanapudi Ravindranath, MBBS, Kevin H. M. Kuo, MDMSc,FRCPC, Sujit Sheth, MD, Janet L. Kwiatkowski, MD MSCE, Lei Hua, PhD, Peter F. Hawkins, PhD, Chris Mix, MD, Bertil Glader, MD PhD

Blood (2019) 134 (Supplement_1): 3512.

https://doi.org/10.1182/blood-2019-123406

Published: 2019

Journal Articles

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Bruno Fattizzo, MD, Marc Michel, Laetitia Languille, Juri Giannotta, MD, Henrik Frederiksen, MD Prof, Francesca Romana Mauro, MD, Bernd Jilma, Elisa Lucchini, MD, Andrea Patriarca, MD, Francesco Zaja, MD, Anita Hill, MD PhD, Sigbjorn Berentsen, MD PhD, Wilma Barcellini

Blood (2019) 134 (Supplement_1): 3516.

https://doi.org/10.1182/blood-2019-125524

Published: 2019

Journal Articles

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 3545.

https://doi.org/10.1182/blood-2019-122685

Published: 2019

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 3518.

https://doi.org/10.1182/blood-2019-126509

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Diego Villa, MD MPH, Laurie H Sehn, MD, Kerry J Savage, BSc, MD MSc, Cynthia L Toze, MD FRCPC, Kevin Song, MD, Wendie L den Brok, Ciara L Freeman, MSc, MBBChir, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 2814.

https://doi.org/10.1182/blood-2019-124217

Published: 2019

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

https://doi.org/10.1182/blood-2019-121841

Published: 2019

Journal Articles

Characterization of Pathogenic Variants Associated with Hereditary Thrombocytopenias in Families from the Czech Republic

Zuzana Vrzalova, PhD, Katerina Stano Kozubik, PhD, Lenka Radova, PhD, Jakub Trizuljak, MD, Sarka Pospisilova, Prof PhD, Michael Doubek, MD PhD

Blood (2019) 134 (Supplement_1): 2343.

https://doi.org/10.1182/blood-2019-122696

Published: 2019

NARROW

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

How I treat warm autoimmune hemolytic anemia

Management of pyruvate kinase deficiency in children and adults

Plasma EDA Fibronectin in Primary Myelofibrosis Correlates with Bone Marrow Fibrosis and Predicts Splenomegaly

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Second-Line Therapy for Immune Thrombocytopenia: Real-World Experience

Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)

Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency

Erythropoietin Downregulates Red Blood Cell Clearance in Mice

Development of Patient-Reported Outcome Measures (Symptoms and Impacts) in Adults with Pyruvate Kinase Deficiency

Oryzocytosis: A Novel Morphological Variant of Hereditary Elliptocytosis Associated with a Novel Mutation in β-Spectrin ( SPTB c154 C>T p.Arg52Trp)

Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency

Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Bendamustine and Rituximab As Induction Therapy in Both Transplant Eligible and Ineligible Patients with Mantle Cell Lymphoma

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Characterization of Pathogenic Variants Associated with Hereditary Thrombocytopenias in Families from the Czech Republic

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only